Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOX1416 in Diabetic Foot Ulcers
NCT06020664Phase 1Suspended
- Sponsor
- NOxy Health Products
- Start
- Aug 2023
- Primary completion
- Sep 2024
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in diabetic foot ulcer (DFU) comparing NOX1416 + SOC with Placebo + SOC (2 arms). Primary endpoint: Proportion of subjects with complete wound closure at 12 weeks. Started Aug 2023; status: suspended.
02
Drugs
NOX-1416 + SOC
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT06020664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06020664.